Benefit of olaparib maintenance

Benefit of olaparib maintenance in 140 patients with ovarian cancer – ESMO Open

ESMO Open shared a post on X about a recent paper by Claudia Marchetti et al. published in ESMO Open:

“Benefit of olaparib maintenance in 140 patients with ovarian cancer, by BRCA mutation type and site. BRCA1-mutated patients in the RING or BRCT and BRCA2-mutated in the RAD51-BD appear to have the greatest benefit from adjuvant olaparib.”

Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study

Authors: Claudia Marchetti et al.

Benefit of olaparib maintenance

Explore more insights and listen to podcast on Ovarian Cancer on OncoDaily.

Benefit of olaparib maintenance

Benefit of olaparib maintenance

BRCT cancer Claudia Marchetti ESMO Open OncoDaily Oncology Ovarian Cancer RING